胃食管反流病的免疫机制的研究进展—免疫炎症级联反应正成为新的治疗靶点

doi:10.3877/cma.j.issn.2095-7157.2022.03.006

中华胃肠内镜电子杂志 ›› 2022, Vol. 09 ›› Issue (03) : 145 -147. doi: 10.3877/cma.j.issn.2095-7157.2022.03.006

综述

胃食管反流病的免疫机制的研究进展—免疫炎症级联反应正成为新的治疗靶点

陈倩倩¹, 李毅¹, 令狐恩强¹^,^†(

)

^1. 100853　北京，解放军总医院第一医学中心消化内科医学部

收稿日期:2022-03-22 出版日期:2022-08-15
通信作者: 令狐恩强
基金资助:
中国博士后基金特别资助(2020TQ0131)

Research progress on immune mechanism of gastroesophageal reflux disease: immune inflammatory cascade acting as a novel therapeutic target

Qianqian Chen¹, Yi Li¹, Enqiang Linghu¹^,^†()

^1. Department of Gastroenterology, The First Center Chinese PLA General Hospital, Beijing 100853, China

Received:2022-03-22 Published:2022-08-15
Corresponding author: Enqiang Linghu

全文 ( ) 下载PDF ( ) 导出引用

胃食管反流病(GERD)是胃十二指肠内容物反流进入食管引起的临床表现和病理变化的一组疾病。近年来针对GERD的发病机制的研究发现，在反流物导致黏膜损伤前，免疫炎症反应早已发生并导致上皮细胞发生变化，继而修复机制被激活。其中，酸/非酸反流是诱导免疫和炎症反应的关键因素。因此，开发一种能够有效地阻断由反流引起的炎症级联反应发生的新靶点，将是一种有前途的GERD治疗方法。

关键词: 胃食管反流病, 免疫, 炎症, 发病机制, 治疗

Gastroesophageal reflux disease (GERD) is a group of diseases with clinical manifestations and pathological changes caused by gastroduodenal content reflux into esophagus. Recently, some researchers have found that before the mucosal injury, the immune response occurred and caused the epithelial cells to vary in the pathogenesis of GERD. Meantime, the repair mechanism was activated, and acid / non acid reflux was the factor inducing immune and inflammatory response. So, to develop a novel treatment target, which can effectively block the occurrence of inflammatory cascade reaction attributed to reflux, would be a promising treatment of GERD.

Key words: Gastroesophageal reflux disease, Immune, Inflammatory, Pathogenesis, Treatment

图1 胃食管反流病的免疫炎症机制

[1]	Gyawali C, Prakash, Kahrilas Peter J，et al. Modern diagnosis of GERD: the Lyon Consensus[J]．Gut，2018，67(7): 1351-1362.
[2]	Katz Philip O, Dunbar Kerry B, Schnoll-Sussman Felice H, et al. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease[J]．Am J Gastroenterol，2022，117(1): 27-56.
[3]	Richter JE, Rubenstein JH. Presentation and Epidemiology of Gastroesophageal Reflux Disease[J]. Gastroenterology，2018，154(2):267-276.
[4]	Fock KM, Talley N, Goh KL, et al. Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett′s oesophagus[J]．Gut，2016，65(9):1402-15.
[5]	Tariq Muhammad Ali, Ahmed Bilal. Combination Treatment With Proton Pump Inhibitor Plus Prokinetic for Gastroesophageal Reflux Disease[J]．J Neurogastroenterol Motil，2022，28(1): 164.
[6]	Nikolic M, Schwameis K, Paireder M，et al. Tailored modern GERD therapy-steps towards the development of an aid to guide personalized anti-reflux surgery[J]. Sci Rep，2019，9(1): 19174.
[7]	Iwakiri Katsuhiko, Fujiwara Yasuhiro, Manabe Noriaki, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021[J]．J Gastroenterol, 2022, 57(4): 267-285.
[8]	Dunbar KB, Agoston AT, Odze RD, et al. Association of Acute Gastroesophageal Reflux Disease With Esophageal Histologic Changes[J]．JAMA，2016, 315(19):2104-1012.
[9]	Souza RF, Huo X, Mittal V, et al. Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanism rather than caustic acid injury [J]．Gastroenterology，2009，137(5): 1776-1784.
[10]	Nan Li, Nam Hyeon Hwa, Choo Byung Kil，et al. Allium hookeriAn Ethanolic Extract of Root Alleviates Reflux Esophagitis and Modulates NF-B Signaling[J]．Evid Based Complement Alternat Med，2018，2018: 1834681.
[11]	Nejat Pish-Kenari F, Qujeq D, Maghsoudi H. Some of the effective factors in the pathogenesis of gastro-oesophageal reflux disease[J]. J Cell Mol Med，2018，22(12):6401-6404.
[12]	Huo X, Zhang X, Yu C，et al. In oesophageal squamous cells exposed to acidic bile salt medium omeprazole inhibits IL-8 expression through effects on nuclear factor-κB and activator protein-1[J]. Gut，2014，63(7):1042-1052.
[13]	Yu Hai-Xiang, Wang Xiao-Long, Zhang Le-Ning, et al. Involvement of the TLR4/NF-κB Signaling Pathway in the Repair of Esophageal Mucosa Injury in Rats with Gastroesophageal Reflux Disease[J]．Cell Physiol Biochem, 2018, 51(4): 1645-1657.
[14]	Hait Elizabeth J, McDonald Douglas R. Impact of Gastroesophageal Reflux Disease on Mucosal Immunity and Atopic Disorders[J]．Clin Rev Allergy Immunol, 2019，57(2):213-225.

[1]	衣晓丽, 胡沙沙, 张彦. HER-2低表达对乳腺癌新辅助治疗疗效及预后的影响[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 340-346.
[2]	伍秋苑, 陈佩贤, 邓裕华, 何添成, 周丹. 肠道微生物在乳腺癌中的研究进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 362-365.
[3]	谭巧, 苏小涵, 侯令密, 黎君彦, 邓世山. 乳腺髓样癌的诊治进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 366-368.
[4]	周婉丽, 钱铮, 李喆. 槐耳在乳腺癌免疫治疗中的研究进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 369-371.
[5]	杨小菁, 姜瑞瑞, 石玉香, 王静静, 李长天. 乳腺孤立性纤维性肿瘤一例[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 375-377.
[6]	姚咏明. 如何精准评估烧伤脓毒症患者免疫状态[J]. 中华损伤与修复杂志(电子版), 2023, 18(06): 552-552.
[7]	钱龙, 陆晓峰, 王行舟, 杜峻峰, 沈晓菲, 管文贤. 神经系统调控胃肠道肿瘤免疫应答研究进展[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 86-89.
[8]	彭旭, 邵永孚, 李铎, 邹瑞, 邢贞明. 结肠肝曲癌的诊断和外科治疗[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 108-110.
[9]	马伟强, 马斌林, 吴中语, 张莹. microRNA在三阴性乳腺癌进展中发挥的作用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 111-114.
[10]	陈垚, 徐伯群, 高志慧. 改良式中间上入路根治术治疗甲状腺癌的有效性安全性研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 619-622.
[11]	陆志峰, 周佳佳, 梁舒. 虚拟现实技术在治疗弱视中的临床应用研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(08): 891-895.
[12]	李田, 徐洪, 刘和亮. 尘肺病的相关研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(08): 900-905.
[13]	岳瑞雪, 孔令欣, 郝鑫, 杨进强, 韩猛, 崔国忠, 王建军, 张志生, 孔凡庭, 张维, 何文博, 李现桥, 周新平, 徐东宏, 胡崇珠. 乳腺癌HER2蛋白表达水平预测新辅助治疗疗效的真实世界研究[J]. 中华临床医师杂志(电子版), 2023, 17(07): 765-770.
[14]	符梅沙, 周玉华, 李慧, 薛春颜. 淋巴细胞免疫治疗对复发性流产患者外周血T淋巴细胞亚群分布与PD1/PD-L1表达的影响及意义[J]. 中华临床医师杂志(电子版), 2023, 17(06): 726-730.
[15]	李变, 王莉娜, 桑田, 李珊, 杜雪燕, 李春华, 张兴云, 管巧, 王颖, 冯琪, 蒙景雯. 亚低温技术治疗缺氧缺血性脑病新生儿的临床分析[J]. 中华临床医师杂志(电子版), 2023, 17(06): 639-643.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Research progress on immune mechanism of gastroesophageal reflux disease: immune inflammatory cascade acting as a novel therapeutic target

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Research progress on immune mechanism of gastroesophageal reflux disease: immune inflammatory cascade acting as a novel therapeutic target